Table 1: Patient characteristics and outcome.
|
# |
Age |
Gen-der |
Immuno- phenotype |
Status |
High risk cyto- genetics |
Previous aHSCT |
Best response |
Blast count in BM pre Mel/Ara-C |
Blast count in BM post Mel/Ara-C1 |
aHSCT following Mel/Ara-C |
EFS (mo.) |
OS (mo.) |
Status of last follow-up |
|
1 |
18.0 |
f |
cALL |
Third relapse |
No |
Yes |
CR |
13% |
MRD neg. post aHSCT |
MMFD |
42 |
42 |
Dead |
|
2 |
1.1 |
m |
Pro-B-ALL |
Primary refractory |
t(4;11) MLL-AF4 rearrangement |
No |
CR |
50% |
MRD neg. post aHSCT |
MUD |
4* |
75 |
Alive in remission |
|
3 |
6.2 |
f |
Mixed phenotype AL |
Primary refractory |
Complex karyotype |
No |
CR |
27% |
MRD neg. |
MMFD |
2 |
4 |
Dead |
|
4 |
11.8 |
f |
AML M2 |
Second relapse |
AML/ETO- fusion transcript (8:21) and c-kit-mutation |
Yes |
CR |
80% |
MRD neg. |
MMFD |
12 |
12 |
Dead |
|
5 |
5.6 |
m |
ALL |
Third relapse |
t(9;11) MLL-AF9 rearrangement |
Yes |
TF |
85% |
12% blasts |
No |
NA |
2 |
Dead |
|
6 |
1.3 |
f |
pro-B-ALL |
Primary refractory |
t(4;11) MLL-AF4 rearrangement |
No |
TF |
MRD 2% |
MRD 4% |
No2 |
NA |
50 |
Alive in remission |
|
7 |
13.9 |
m |
T-lympho- blastic lymphoma stage III |
First relapse |
No |
No |
CR |
40% |
MRD neg. post aHSCT |
MMFD |
2 |
3 |
Dead |
|
8 |
13.1 |
f |
AML M2 auer |
First relapse |
Mutation in NRAS- and WT1-gene |
Yes |
TF |
MRD 0.4% |
5 -7% blasts |
No3 |
NA |
2 |
Dead |
1In three cases only a remission in peripheral blood was documented between the salvage therapy and the allogeneic HSCT and a bone marrow puncture was performed after the a HSCT;
2This patient received three cycles of clofarabine, cyclophosphamide and etoposide afterwards and was transplanted subsequently;
3This patient received one cycle of clofarabine, cyclophosphamide, etoposide and cytarabine afterwards and was transplanted subsequently; *This patient developed multiple chloromas, which were irradiated. In addition, he received 4 cycles of blinatumomab followed by another stem cell transplantion.
AHSCT: Allogeneic Hematopoietic Stem Cell Transplantation; ALL: Acute Lymphoblastic Leukemia; AML: Acute Myeloid Leukemia; BM: Bone Marrow; CR: Complete Remission; EFS: Event Free Survival; F: Female; M: Male; Mel/Ara-C: Melphalan/Cytarabine; MMFD: Mismatched Family Donor; MRD: Minimal Residual Disease; MUD: Matched Unrelated Donor; NA: Not Available; OS: Overall Survival; TF: Treatment Failure